These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23136226)

  • 1. Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma.
    Romano A; Chiarenza A; Consoli U; Conticello C; Forte S; Uccello G; Vetro C; Cavalli M; Coppolino F; Palumbo GA; Di Raimondo F
    Ann Oncol; 2013 Apr; 24(4):1038-44. PubMed ID: 23136226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
    Fukushima T; Nakamura T; Iwao H; Nakajima A; Miki M; Sato T; Sakai T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Nakajima H; Motoo Y; Umehara H
    Anticancer Res; 2011 Jun; 31(6):2297-302. PubMed ID: 21737655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
    Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
    Romano A; Chiarenza A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Cunsolo R; Palumbo GA; Di Raimondo F
    Eur J Haematol; 2014 Sep; 93(3):207-13. PubMed ID: 24673398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
    Terpos E; Kastritis E; Roussou M; Heath D; Christoulas D; Anagnostopoulos N; Eleftherakis-Papaiakovou E; Tsionos K; Croucher P; Dimopoulos MA
    Leukemia; 2008 Dec; 22(12):2247-56. PubMed ID: 18769451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
    Mangiacavalli S; Pochintesta L; Pascutto C; Cocito F; Pompa A; Cazzola M; Corso A
    Am J Hematol; 2013 Feb; 88(2):102-6. PubMed ID: 23224960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
    Harrison SJ; Quach H; Link E; Seymour JF; Ritchie DS; Ruell S; Dean J; Januszewicz H; Johnstone R; Neeson P; Dickinson M; Nichols J; Prince HM
    Blood; 2011 Dec; 118(24):6274-83. PubMed ID: 21911830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
    Kobayashi T; Kuroda J; Fuchida S; Murakami S; Hatsuse M; Okano A; Iwai T; Tsutsumi Y; Kamitsuji Y; Akaogi T; Kawata-Iida E; Shimizu D; Uchiyama H; Matsumoto Y; Horiike S; Nakao M; Takahashi R; Kaneko H; Uoshima N; Kobayashi Y; Shimazaki C; Taniwaki M
    Intern Med; 2013; 52(9):961-8. PubMed ID: 23648714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
    Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V
    Leuk Lymphoma; 2013 Mar; 54(3):555-60. PubMed ID: 22881043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
    Ludwig H; Kasparu H; Leitgeb C; Rauch E; Linkesch W; Zojer N; Greil R; Seebacher A; Pour L; Weißmann A; Adam Z
    Blood; 2014 Feb; 123(7):985-91. PubMed ID: 24227817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
    Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Grishunina M; Rekhtman G; Masliak Z; Robak T; Shubina A; Arnulf B; Kropff M; Cavet J; Esseltine DL; Feng H; Girgis S; van de Velde H; Deraedt W; Harousseau JL
    Lancet Oncol; 2011 May; 12(5):431-40. PubMed ID: 21507715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].
    Bao L; Lu XJ; Zhang XH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1829-31. PubMed ID: 19040018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
    Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R
    Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
    Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG
    Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bortezomib in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma].
    Yuan ZG; Hou J; Zhou F; Fu WJ; Chen YB; Xi H; Yang SL
    Zhonghua Xue Ye Xue Za Zhi; 2006 Oct; 27(10):653-5. PubMed ID: 17343194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
    Lee SS; Suh C; Kim BS; Chung J; Joo YD; Ryoo HM; Do YR; Jin JY; Kang HJ; Lee GW; Lee MH; Shim H; Kim K; Yoon SS; Bang SM; Kim HY; Lee JJ; Park J; Lee DS; Lee JH;
    Ann Hematol; 2010 Sep; 89(9):905-12. PubMed ID: 20349060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
    Sharma M; Khan H; Thall PF; Orlowski RZ; Bassett RL; Shah N; Bashir Q; Parmar S; Wang M; Shah JJ; Hosing CM; Popat UR; Giralt SA; Champlin RE; Qazilbash MH
    Cancer; 2012 May; 118(9):2507-15. PubMed ID: 21887685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.